Navigation Links
Exelixis, Inc., Analyst Report; The Upside Potential is Worth the Risk by BrokerBank Securities, Inc.
Date:7/17/2014

NEW YORK, July 17, 2014 /PRNewswire/ -- Exelixis, Inc. (Nasdaq: EXEL) is a development stage biotech company. EXEL developed two cancer treatments cabozantinib (Cabo, Cometriq) and cobimetinib (Cobi). Both use small molecules as the active component. The company has a partnership with Roche to commercialize, market and distribute cobi. Cobi is expected to earn approval in the treatment of melanoma by late 2015, after positive phase-three trial results earlier this week. Cabo is marketed and distributed in the U.S. by EXEL, and in Europe by Sobi. Sobi receives an undisclosed management fee. European revenues are expected in Q2 after a March European approval. Cabo is currently only approved to treat a specific type of thyroid cancer, MTC. There are between 500-700 new cases per year in the U.S., and treatment costs $10,395 for a 28-day supply. In addition, the company has five phase-three trials for various cancer treatments. On top of those, the company has numerous partnerships with other drug companies, and multiple treatments in phase two trials. EXEL has a huge pipeline of potential uses for cabo and cobi.

The company's stock has been hammered by short sellers and recent events. The stock price is down 64% from its 52-week high of $8.41 and now trades at $3.64. The short interest as a percentage of the float is 27%. People are very bearish on EXEL. The price tanked after news in March from the mid-point of one of the company's phase-three trials. I believe the potential is there run the stock price to run back up.

A full in-depth analyst report on CBDS that includes risk factors, industry review, financial position, potential revenues, review of current business model, competition breakdown, analyst summary, and recommendation can be viewed by using the following link at no cost:

http://bit.ly/-EXEL-AnalystReport

Copy and paste to browser may be required.

This report was prepared for informational purposes only. Affiliated parties involved with producing and issuing this report have not been compensated in any form. A full disclaimer can be found by viewing the full analyst report.

FORWARD-LOOKING DISCLAIMER   

This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.   

COMPLIANCE PROCEDURE   

Content is researched, written and reviewed on a best-effort basis. This document, article or report is written and authored by Fred Rockwell, CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.


'/>"/>
SOURCE BrokerBank Securities, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Public Offerings of Common Stock, Financial Results, and Significant Progress in Key Development Programs - Research Report on BioCryst, Exelixis, Idenix, Puma Biotechnology, and Halozyme
2. Strides Arcolab makes strategic investment in Oncobiologics, Inc., USA
3. Neurotrope, Inc., to Present at Biotech Showcase 2014 in San Francisco
4. Anterios, Inc., Announces Results of Consumer Survey Revealing Widespread Problem of Excessive Sweating and Desire for New Topical Botulinum Toxin Treatment
5. Telomere Diagnostics, Inc. (TDx), previously known as Telome Health, Inc., announces its name change
6. MELA Sciences, Inc., a Leader in the Fight Against Melanoma, Participates in the American Society of Dermatologic Surgery Annual Meeting
7. Topical BioMedics, Inc., Signs on With CVS Pharmacy; Topricin® Foot Therapy Cream to be Carried in the Retailer’s Foot Care Section
8. Technical Study: Gilead Sciences Inc., Halozyme Therapeutics Inc., NPS Pharmaceuticals Inc., and InterMune Inc.
9. Neurotrope, Inc., Announces New Trading Symbol
10. Before the Bell Scans: Hologic Inc., St. Jude Medical Inc., ResMed Inc., and Navidea Biopharmaceuticals Inc.
11. First Warning Systems, Inc., Retains Joshua D.I. Ellenhorn, M.D., as Principal Investigator
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Regular discussions on a range of subjects ... the two entities said Poloz. Speaking at a ... , he pointed to the country,s inflation target, which ... "In certain areas ... have common economic goals, why not sit down and address ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... Md. , June 23, 2016 A person ... from the crime scene to track the criminal down. ... the U.S. Food and Drug Administration (FDA) uses DNA evidence ... Sound far-fetched? It,s not. The FDA ... sequencing to support investigations of foodborne illnesses. Put as simply ...
(Date:6/23/2016)... NEW YORK , June, 23, 2016  The ... students to envision new ways to harness living systems ... of Modern Art (MoMA) in New York ... more than 130 participating students, showcased projects at MoMA,s ... included Paola Antonelli , MoMA,s senior curator of ...
Breaking Biology Technology:
(Date:5/16/2016)... NEW YORK , May 16, 2016   ... authentication solutions, today announced the opening of an IoT ... to strengthen and expand the development of embedded ... provides an unprecedented level of convenience and security with ... to authenticate one,s identity aside from DNA. EyeLock,s platform ...
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
(Date:4/28/2016)... FRANCISCO and BANGALORE, India , ... of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... provider, today announced a global partnership that will ... way to use mobile banking and payment services. ... is a key innovation area for financial services, but it ...
Breaking Biology News(10 mins):